Abstract Number: 2546 • 2017 ACR/ARHP Annual Meeting
Secukinumab Decreases Arterial Wall Inflammation in Patients with Peripheral Spondyloarthritis
Background/Purpose: Patients with spondyloarthritis (SpA), a chronic inflammatory disease, have an increased cardiovascular risk, which is partly due to increased inflammatory activity in the arterial…Abstract Number: 2547 • 2017 ACR/ARHP Annual Meeting
the Ideal Target for Psoriatic Arthritis? Comparison of Remission and Low Disease Activity States in a Real Life Cohort
Background/Purpose: Recommendations on psoriatic arthritis (PsA) state that the target of treatment should be remission or inactive disease with an alternative target of minimal or…Abstract Number: 2548 • 2017 ACR/ARHP Annual Meeting
Validation of New Potential Targets for Remission and Low Disease Activity in Psoriatic Arthritis in Patients Treated with Golimumab
Background/Purpose: Treat to target recommendations in PsA state that the target of treatment should be remission or low disease activity (LDA). So far, the only…Abstract Number: 2549 • 2017 ACR/ARHP Annual Meeting
Achievement of Minimal Disease Activity Is Associated with Improvements in Health-Related Quality of Life and Productivity in Psoriatic Arthritis Patients
Background/Purpose: Treatment goals in psoriatic arthritis (PsA) are moving toward attainment of absolute therapeutic thresholds rather than relative improvement. Minimal disease activity (MDA), a composite…Abstract Number: 2550 • 2017 ACR/ARHP Annual Meeting
A New and Simpler Tool for Global Psoriatic Arthritis Assessment: Simplified Composite Psoriatic Disease Activity Index (sCPDAI)
Background/Purpose: The heterogeneity of psoriatic arthritis ( PsA) that includes a possible combination of axial disease, peripheral arthritis, enthesitis, dactylitis, skin and nail involvement, makes…Abstract Number: 2551 • 2017 ACR/ARHP Annual Meeting
Comparison between Two Cut-Off Values of Disease Activity in Psoriatic Arthritis Index and Validation of Its Simplified Clinical Version in Patients with Psoriatic Arthritis
Background/Purpose: Two groups established cut-off values for Disease Activity Index for Psoriatic Arthritis (DAPSA)1-2. The clinical DAPSA (cDAPSA) excludes CRP from its calculation and the…Abstract Number: 2552 • 2017 ACR/ARHP Annual Meeting
Inter-Connections between Fatigue, Pain and Patient Global Assessement in Patients with Active Spondyloarthritis Followed in the Daily Clinic
Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) has selected fatigue, pain and patient global assessment (PaGl) as key patient-reported outcome measures in clinical trials…Abstract Number: 2553 • 2017 ACR/ARHP Annual Meeting
Patient and Physician Global Assessment Are Poorly Inter-Connected and Poorly Explained By Other Clinical Markers of Disease Activity in Individual Patients with Psoriatic Arthritis
Background/Purpose: Assessment of disease activity is important in the evaluation and monitoring of patients with psoriatic arthritis (PsA) in clinical care and research. As there…Abstract Number: 2554 • 2017 ACR/ARHP Annual Meeting
Disease Activity in Psoriatic Arthritis-ESR Index Maybe a Valid Tool to Evaluate Disease Activity in Patients with Psoriatic Arthritis When CRP Is Not Available
Background/Purpose: DAPSA is a composite index to assess disease activity in patients with Psoriatic Arthritis (PsA) which includes joint count 66/68, pain and patient´s global…Abstract Number: 2555 • 2017 ACR/ARHP Annual Meeting
Clinical History of Psoriatic Arthritis over Four Decades
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease associated with psoriasis. Over the past several decades it was recognized that PsA is more common…Abstract Number: 2556 • 2017 ACR/ARHP Annual Meeting
Were Moll and Wright Right?
Background/Purpose: In 1973 Moll and Wright published the first paper on the classification criteria for Psoriatic Arthritis (PsA). In their pioneering work, these authors additionally…Abstract Number: 2557 • 2017 ACR/ARHP Annual Meeting
Do Psoriatic Disease Patients Who Participate in Clinical Research Differ from Those Who Do Not?
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease that affects 30% of people with psoriasis. The current understanding of these diseases involves patients who…Abstract Number: 2558 • 2017 ACR/ARHP Annual Meeting
DNA Methylation-Dependent Regulation of Cathepsin E Gene Expression By the Transcription Factor Kaiso in MRL/Lpr Mice
Background/Purpose: To identify new candidate genes regulated by DNA methylation and involved in the pathogenesis of systemic lupus erythematosus (SLE), we integrated genome-wide DNA methylation…Abstract Number: 2559 • 2017 ACR/ARHP Annual Meeting
KZR-616, a Selective Inhibitor of the Immunoproteasome, Blocks the Disease Progression in Multiple Models of Systemic Lupus Erythematosus (SLE)
Background/Purpose: The proteasome inhibitor bortezomib has been used successfully to treat patients with SLE. The immunoproteasome is a distinct class of proteasome found predominantly in…Abstract Number: 2560 • 2017 ACR/ARHP Annual Meeting
Spleen Tyrosine Kinase Inhibition Reveals Immune Cell Subsets of Diseased NZB/W F1 Mice That Are Reflected in Systemic Lupus Erythematosus Patient Peripheral Blood Mononuclear Cells
Background/Purpose: Spleen tyrosine kinase (SYK) is a driver of B cell receptor and Fc receptor signaling pathways, which have central roles in initiating and driving…
ACR Meeting Abstracts